425: NextCure to Merge with Avere Therapeutics in All-Stock Deal

NextCure and Avere Therapeutics have entered into a definitive merger agreement for an all-stock transaction, combining Avere's oral IL-23 program with NextCure's public market infrastructure.

Summary

• NextCure, Inc. (NXTC) and Avere Therapeutics, Inc. have signed a definitive merger agreement for an all-stock transaction.
• The merger aims to accelerate the development of Avere's lead program, AVR-001, an oral peptide interleukin-23 (IL-23) receptor antagonist.
• A concurrent private placement of $320 million, led by Fairmount and Hansoh Pharmaceutical Group, will fund the combined company.
• The combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVRX.
• The transaction is expected to close in the second half of 2026, subject to customary closing conditions, including stockholder approvals.
• NextCure stockholders will receive contingent value rights (CVRs) entitling them to 90% of net proceeds from future monetization of NextCure's pipeline assets over two years.
• Avere's experienced management team, which previously guided Akero Therapeutics, will lead the combined company.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, driven by a strong clinical candidate, substantial financing, and an experienced management team, positioning the combined entity for potential success in a growing market.

Positives

• Avere's lead program, AVR-001, has demonstrated promising Phase 1b psoriasis data, supporting its potential as a convenient, once-weekly oral therapy.
• The concurrent $320 million private placement provides significant capital to advance AVR-001 through key clinical milestones, including a Phase 2b readout in psoriasis and initiation of Phase 3 trials.
• The combined company will be led by a seasoned management team with a proven track record in the biotech industry.
• The merger provides NextCure stockholders with CVRs, offering potential upside from the monetization of NextCure's existing pipeline assets.
• The transaction is expected to result in a well-capitalized entity positioned to compete in the oral IL-23 market.

Negatives

• The exchange ratio is subject to adjustment based on NextCure's net cash position prior to closing.
• The success of AVR-001 is dependent on future clinical trial results, which carry inherent risks.
• The CVRs are contingent on future monetization of NextCure's pipeline assets, with no assurance of payment.
• The merger involves a significant shift in ownership, with pre-merger Avere stockholders expected to own approximately 98.79% of the combined company.

Risks

• Failure to obtain necessary stockholder approvals or satisfy other closing conditions could prevent the merger from being completed.
• Clinical development of AVR-001 may encounter unforeseen delays, safety issues, or fail to demonstrate efficacy, leading to regulatory non-approval.
• The highly competitive landscape for IL-23-driven inflammatory diseases presents a risk to market penetration and commercial success.
• The combined company's ability to manage expenses and integrate operations effectively is critical for future financial performance.
• The company's reliance on in-licensed intellectual property from Hansoh carries risks related to the terms of the license agreement and potential disputes.
• The market acceptance and commercial success of AVR-001 are not guaranteed, even with positive clinical data.

Future Outlook

The combined company, Avere Therapeutics, Inc., is expected to be well-capitalized through the $320 million private placement, enabling it to advance AVR-001 through Phase 2b trials in psoriasis and initiate a Phase 2b trial in ulcerative colitis. The company anticipates a clear path to value-generating clinical data.

Management Comments

• "The combination of the strong clinical data from Hansohs Phase 1b psoriasis study, the capital raised through this financing from a world-class investor syndicate, and immediate access to the public markets positions us to be highly competitive in the emerging oral IL-23 market," said Andrew Cheng, MD, PhD, CEO of Avere.
• "We have a clear line of sight to potentially value-generating clinical data and the resources to execute our plans. We are focused on rapidly delivering a once-weekly oral IL-23 therapy that combines best-in-class convenience with efficacy competitive with other emerging oral IL-23 therapies."
• "Since our founding, NextCure has been committed to advancing innovative therapies designed to improve outcomes for patients. I am incredibly proud of the dedication, talent, and perseverance of the NextCure team and the important contributions they have made in pursuit of our mission," said Michael Richman, President and CEO of NextCure.
• "We are pleased to announce this transaction with Avere, which represents a compelling opportunity for NextCures stockholders to participate in the development of once-weekly AVR-001 and its significant therapeutic and commercial potential."
• "NextCures Board of Directors and management team are in full support of this transaction, and we believe Averes strong balance sheet and experienced management team are well-positioned to successfully execute on the development plans for AVR-001."

Industry Context

StockSavvy.ai notes that this merger aligns with the growing trend of biopharmaceutical companies seeking public market access and capital to advance promising drug candidates, particularly in the competitive inflammatory disease space. The focus on an oral IL-23 therapy addresses a market need for convenient treatment options, potentially disrupting the current landscape dominated by injectable biologics.

Comparison to Industry Standards

• Avere's lead program, AVR-001, aims for once-weekly oral dosing, a significant convenience advantage compared to existing injectable IL-23 therapies like Skyrizi (risankizumab) and Tremfya (guselkumab), which require less frequent but still injectable administration.
• The reported Phase 1b data showing PASI and PASI 75 responses comparable to first-generation daily oral IL-23 inhibitors (e.g., Xeljanz, though not an IL-23 inhibitor, it represents an oral small molecule approach) after only four weeks of dosing suggests potential for durable pharmacodynamic activity, a key differentiator.
• The $320 million private placement is substantial for a company at this stage, indicating strong investor confidence, comparable to other well-capitalized biotech financings in the inflammatory disease sector.

Management Changes

Stakeholder Impact

• NextCure stockholders will receive CVRs, providing potential future value from existing pipeline assets, alongside a small equity stake in the combined company.
• Avere stockholders and investors in the private placement will gain access to public markets and a significantly capitalized entity focused on advancing AVR-001.
• Employees of both companies may face integration challenges and potential workforce adjustments, though specific details are not provided.
• The management team of Avere will lead the combined entity, bringing their expertise to the development and commercialization of AVR-001.

Next Steps

• Obtain stockholder approvals from both NextCure and Avere.
• File a registration statement on Form S-4 with the SEC.
• Complete the merger transaction, expected in the second half of 2026.
• Begin development of AVR-001, including initiating a Phase 2b study in psoriasis in early 2027.
• Monetize NextCure's existing pipeline assets through the CVR arrangement.

Key Dates

Recommendation

The merger presents a strong clinical candidate with significant financing and experienced management, but the inherent risks in clinical development and the small initial ownership for NextCure stockholders warrant a 'hold' recommendation pending further clinical data and market progress.

Keywords

NextCure, Avere Therapeutics, Merger Agreement, Biotechnology, AVR-001, IL-23, Psoriasis, Clinical Trials